Fluoroquinolones: Is Another FDA Safety Step Needed?
This article was originally published in The Pink Sheet Daily
Executive Summary
Joint advisory committee meeting will discuss post-marketing safety data, including adverse events across organ systems.
You may also be interested in...
Fluoroquinolones Get New Safety Labeling, But Not A REMS
Risk of disabling, potentially permanent serious side effects that can occur together will be added to Cipro, Levaquin labels along with limitation against use for some self-limiting conditions unless there are no alternative treatments.
FDA Adverse Event Data Clouds Potential Fluoroquinolone Label Changes
Advisory committee unsure how to describe fluoroquinolone-associated disability in labeling.
Fluoroquinolones Need REMS With Communication Plan, AdCom Says
Overwhelming votes against existing labels for the antibiotics likely means sponsors and FDA have some safety planning to do.